Aim: The aim of this analysis was to compare the effectiveness of rosuvastatin in lowering cholesterol with that of atorvastatin in patients at high risk of dyslipidaemia.

Place and Duration: In the Medicine department of Islam Medical College and Teaching Hospital Sialkot for six months duration from June 2021 to November 2021.

Methods: This randomized, open-label study enrolled 90 patients with high-risk dyslipidaemia and diagnosed according to the international guidelines for the prevention of adult dyslipidaemia. These patients were randomized to rosuvastatin and atorvastatin to receive rosuvastatin 20 mg / day and atorvastatin 20 mg / day, respectively, for three months. In both groups, the efficacy of atorvastatin and rosuvastatin on the concentration of LDL-C, HDL-C, total cholesterol (TC) and triglycerides (TG) was assessed. In addition, the rates of achieving LDL-C or TC target levels were assessed in both groups.

Results: Rosuvastatin caused a significantly greater reduction of LDL-C (43.2% and 38.1%, p <0.05) and TC (34.8% Vs 28.1%, p <0.05) than Atorvastatin. In addition, the percentage of subjects attaining the recommended target TC and LDL-C levels was higher in the group of rosuvastatin as compared to the atorvastatin group.

Conclusions: In patients at high risk of hyperlipidemia, rosuvastatin has high efficacy in decreasing lipids than atorvastatin.

Keywords: rosuvastatin, atorvastatin, dyslipidaemia, high-density lipoprotein, triglycerides.